Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
Robert H VonderheideKimberly A KraynyakAnthony F ShieldsAutumn J McReeJennifer M JohnsonWeijing SunAshish V ChintakuntlawarJan PawlickiAlbert J SylvesterTrevor McMullanRobert SamuelsJoseph J KimDavid WeinerJean D BoyerMatthew P MorrowLaurent HumeauJeffrey M SkolnikPublished in: Journal for immunotherapy of cancer (2022)
Plasmid DNA-encoded hTERT/IL-12 DNA immunotherapy was well-tolerated, immune responses were noted across all tumor types, and a specific CD8+ phenotype increased by the immunotherapy was significantly correlated with survival in patients with pancreatic cancer.